Site Editor

Soo Park, MD


Tina J. Hieken, MD, on Treatment Advances in High-Risk Regionally Advanced Melanoma: Clinical Implications

Posted: Monday, April 1, 2024

Tina J. Hieken, MD, of the Mayo Clinic School of Graduate Medical Education, discusses the treatment landscape for patients with high-risk surgically resectable stage III melanoma and explores topics including neoadiuvant immunotherapy, who should still receive adjuvant treatment, and whether it's beneficial to de-escalate adjuvant systemic therapy or the extent of surgery based on pathologic response.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.